CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS  by Storey, Robert F. et al.
E505
JACC March 27, 2012
Volume 59, Issue 13
Acute Coronary Syndromes 
CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME 
PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Sunday, March 25, 2012, 11:00 a.m.-Noon
Session Title: Acute Coronary Syndromes: Clinical VIII
Abstract Category: 4. Acute Coronary Syndromes: Therapy
Presentation Number: 1164-85
Authors: Robert F. Storey, Stefan James, Nils Åsenblad, Agneta Siegbahn, Hakan Emanuelsson, Hugo Katus, Christopher Cannon, Steen Husted, 
Philippe Steg, Lars Wallentin, University of Sheffield, Sheffield, United Kingdom, Uppsala Clinical Research, Uppsala, Sweden
Background: Elevated inflammatory markers are associated with worse outcomes in patients with acute coronary syndromes (ACS). In the Platelet 
Inhibition and Patients Outcomes (PLATO) trial of 18,624 ACS patients, ticagrelor (T) compared to clopidogrel (C) significantly reduced the risk of CV 
death more than that of myocardial infarction (MI).
Methods: Levels of white blood cell count (WBC) and plasma C-reactive protein (CRP) and interleukin (IL) 6 and 10 were analysed in subsets of 
the PLATO safety population who received at least 1 dose of study medication. Rates of the composite primary endpoint (CV death, MI, stroke) and 
all-cause mortality were assessed for each quartile of the baseline biomarker level. Cox proportional hazard regression was used to compare T and 
C within each quartile (Q1-4) and Cochrane-Armitage trend test was used to assess impact of biomarker level on clinical outcome in each treatment 
group.
Results: Increasing WBC was not associated with significantly worse primary endpoint rates in the the T group (n=7378) but was in the C 
group (n=7373): for Q1-4 in the T group, rates were 8.4, 8.1, 8.9 and 8.8% (P=0.44) and in the C group were 9.2, 9.7, 9.8 and 11.4% (P=0.03) 
respectively and WBC did not influence the beneficial effect of T vs C (int P = 0.67). In T and C groups, increasing WBC was associated with increasing 
mortality (both P < 0.001) and T reduced mortality regardless of WBC (int P = 0.89). CRP level was associated with primary endpoint and mortality 
rates in both T (n=8212) and C (n=8192) groups (all P<0.001) and did not influence the beneficial effect of T (int P 0.97 and 0.17): for Q1-4 of CRP, 
mortality rates in the T group were 2.3, 2.6, 4.1 and 7.5% and in the C group were 3.7, 3.3, 4.1 and 9.9% respectively. Similar trends were seen with 
IL6 and IL10.
Conclusion: Higher levels of inflammatory marker at baseline are associated with worse prognosis in ACS patients. The reduction in ischemic 
events and mortality with T compared to C was consistent across different levels of inflammatory activity at baseline.
